Pharmacological modulation of the AKT/microRNA-199a-5p/CAV1 pathway ameliorates cystic fibrosis lung hyper-inflammation

Nature Communications

Volumn 6, Issue , 2015, Pages

  Zhang, Ping Xia ^a   Cheng, Jijun ^a,b   Zou, Siying ^a   D'Souza, Anthony D ^a   Koff, Jonathan L ^a   Lu, Jun ^a,b   Lee, Patty J ^a   Krause, DIane S ^a,b   Egan, Marie E ^a   Bruscia, Emanuela M ^a  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b YALE CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CAVEOLIN 1; CELECOXIB; HYPOXIA INDUCIBLE FACTOR 1ALPHA; INTERLEUKIN 6; MICRORNA; MICRORNA 199A 5P; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE B; TOLL LIKE RECEPTOR 4; UNCLASSIFIED DRUG; MIRN199 MICRORNA, HUMAN; MIRN199 MICRORNA, MOUSE;

CELLS AND CELL COMPONENTS; DRUG; IMMUNITY; MORBIDITY; PROTEIN; RESPIRATORY DISEASE; RNA; RODENT;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIINFLAMMATORY ACTIVITY; ARTICLE; CONTROLLED STUDY; CYSTIC FIBROSIS; DOWN REGULATION; FEMALE; HUMAN; HUMAN CELL; INFLAMMATION; INNATE IMMUNITY; LUNG DISEASE; LUNG HYPERINFLAMMATION; MACROPHAGE; MALE; MOUSE; NONHUMAN; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; ANIMAL; BIOLOGICAL MODEL; C57BL MOUSE; DRUG EFFECTS; ENZYMOLOGY; LUNG; METABOLISM; PATHOLOGY;

MURINAE; MUS;

ANIMALS; CAVEOLIN 1; CELECOXIB; CYSTIC FIBROSIS; HUMANS; INFLAMMATION; LUNG; MACROPHAGES; MICE, INBRED C57BL; MICRORNAS; MODELS, BIOLOGICAL; PHOSPHATIDYLINOSITOL 3-KINASES; PROTO-ONCOGENE PROTEINS C-AKT; SIGNAL TRANSDUCTION; TOLL-LIKE RECEPTOR 4;

EID: 84947038442     PISSN: None     EISSN: 20411723     Source Type: Journal    
DOI: 10.1038/ncomms7221     Document Type: Article

References (70)

1. Chmiel, J. F. & Davis, P. B. State of the art: why do the lungs of patients with cystic fibrosis become infected and why can't they clear the infection? Respir. Res. 4, 8 (2003).
2. Konstan, M. W., Schluchter, M. D., Xue, W. & Davis, P. B. Clinical use of Ibuprofen is associated with slower FEV1 decline in children with cystic fibrosis. Am. J. Respir. Crit. Care Med. 176, 1084-1089 (2007).
3. VanDevanter, D. et al. High dose ibuprofen significantly improves long-term CF survival. Pediatr. Pulmonol. 47, 354-354 (2012).
4. Rowe, S. M. et al. Clinical mechanism of the cystic fibrosis transmembrane conductance regulator potentiator ivacaftor in G551D-mediated cystic fibrosis. Am. J. Respir. Crit. Care Med. 190, 175-184 (2014).
5. Dudez, T. et al. CFTR in a lipid raft-TNFR1 complex modulates gap junctional intercellular communication and IL-8 secretion. Biochim. Biophys. Acta 1783, 779-788 (2008).
6. Vij, N., Mazur, S. & Zeitlin, P. L. CFTR is a negative regulator of NFkappaB mediated innate immune response. PLoS ONE 4, e4664 (2009).
7. Bruscia, E. M. et al. Abnormal trafficking and degradation of TLR4 underlie the elevated inflammatory response in cystic fibrosis. J. Immunol. 186, 6990-6998 (2011).
8. Hartl, D. et al. Innate immunity in cystic fibrosis lung disease. J. Cyst. Fibros 11, 363-382 (2012).
9. Bruscia, E. M. et al. Macrophages directly contribute to the exaggerated inflammatory response in cystic fibrosis transmembrane conductance regulator-/-mice. Am. J. Respir. Cell Mol. Biol. 40, 295-304 (2009).
10. Bonfield, T. L., Hodges, C. A., Cotton, C. U. & Drumm, M. L. Absence of the cystic fibrosis transmembrane regulator (Cftr) from myeloid-derived cells slows resolution of inflammation and infection. J. Leukoc. Biol 92, 1111-1122 (2012).
11. Kelly, C. et al. Toll-like receptor 4 is not targeted to the lysosome in cystic fibrosis airway epithelial cells. Am. J. Physiol. Lung Cell Mol. Physiol. 304, L371-L382 (2013).
12. Zhang, P. X. et al. Reduced caveolin-1 promotes hyperinflammation due to abnormal heme oxygenase-1 localization in lipopolysaccharide-challenged macrophages with dysfunctional cystic fibrosis transmembrane conductance regulator. J. Immunol. 190, 5196-5206 (2013).
13. Wang, X. M., Kim, H. P., Nakahira, K., Ryter, S. W. & Choi, A. M. The heme oxygenase-1/carbon monoxide pathway suppresses TLR4 signaling by regulating the interaction of TLR4 with caveolin-1. J. Immunol. 182, 3809-3818 (2009).
14. Baltimore, D., Boldin, M. P., O'Connell, R. M., Rao, D. S. & Taganov, K. D. MicroRNAs: new regulators of immune cell development and function. Nat. Immunol. 9, 839-845 (2008).
15. Foster, P. S. et al. The emerging role of microRNAs in regulating immune and inflammatory responses in the lung. Immunol. Rev. 253, 198-215 (2013).
16. McKiernan, P. J., Cunningham, O., Greene, C. M. & Cryan, S. A. Targeting miRNA-based medicines to cystic fibrosis airway epithelial cells using nanotechnology. Int. J. Nanomed. 8, 3907-3915 (2013).
17. Ramachandran, S. et al. Post-transcriptional regulation of cystic fibrosis transmembrane conductance regulator expression and function by microRNAs. Am. J. Respir. Cell Mol. Biol. 49, 544-551 (2013).
18. Fabbri, E. et al. Expression of microRNA-93 and Interleukin-8 during Pseudomonas aeruginosa-mediated induction of proinflammatory responses. Am. J. Respir. Cell Mol. Biol. 50, 1144-1155 (2014).
19. Weldon, S. et al. miR-31 dysregulation in cystic fibrosis airways contributes to increased pulmonary cathepsin S production. Am. J. Respir. Crit. Care Med. 190, 165-174 (2014).
20. Lino Cardenas, C. L. et al. miR-199a-5p Is upregulated during fibrogenic response to tissue injury and mediates TGFbeta-induced lung fibroblast activation by targeting caveolin-1. PLoS Genetics 9, e1003291 (2013).
21. Alexander, M. S. et al. MicroRNA-199a is induced in dystrophic muscle and affects WNT signaling, cell proliferation, and myogenic differentiation. Cell Death Differ. 20, 1194-1208 (2013).
22. Mizuno, S. et al. MicroRNA-199a-5p is associated with hypoxia-inducible factor-1alpha expression in lungs from patients with COPD. Chest 142, 663-672 (2012).
23. Rane, S. et al. Downregulation of miR-199a derepresses hypoxia-inducible factor-1alpha and Sirtuin 1 and recapitulates hypoxia preconditioning in cardiac myocytes. Circ. Res. 104, 879-886 (2009).
24. Hassan, T. et al. miR-199a-5p silencing regulates the unfolded protein response in chronic obstructive pulmonary disease and alpha1-antitrypsin deficiency. Am. J. Respir. Crit. Care Med. 189, 263-273 (2014).
25. Ebert, M. S., Neilson, J. R. & Sharp, P. A. MicroRNA sponges: competitive inhibitors of small RNAs in mammalian cells. Nat. Methods 4, 721-726 (2007).
26. Rane, S. et al. An antagonism between the AKT and beta-adrenergic signaling pathways mediated through their reciprocal effects on miR-199a-5p. Cell. Signal. 22, 1054-1062 (2010).
27. Zhang, Y. et al. Kinase AKT controls innate immune cell development and function. Immunology 140, 143-152 (2013).
28. Laird, M. H. et al. TLR4/MyD88/PI3 K interactions regulate TLR4 signaling. J. Leukoc. Biol. 85, 966-977 (2009).
29. Guha, M. & Mackman, N. The phosphatidylinositol 3-kinase-Akt pathway limits lipopolysaccharide activation of signaling pathways and expression of inflammatory mediators in human monocytic cells. J. Biol. Chem. 277, 32124-32132 (2002).
30. Androulidaki, A. et al. The kinase Akt1 controls macrophage response to lipopolysaccharide by regulating microRNAs. Immunity 31, 220-231 (2009).
31. Luyendyk, J. P. et al. Genetic analysis of the role of the PI3K-Akt pathway in lipopolysaccharide-induced cytokine and tissue factor gene expression in monocytes/macrophages. J. Immunol. 180, 4218-4226 (2008).
32. Sonawane, N. D. & Verkman, A. S. Thiazolidinone CFTR inhibitors with improved water solubility identified by structure-activity analysis. Bioorg. Med. Chem. 16, 8187-8195 (2008).
33. Hamdulay, S. S. et al. Celecoxib activates PI-3K/Akt and mitochondrial redox signaling to enhance heme oxygenase-1-mediated anti-inflammatory activity in vascular endothelium. Free Radic. Biol. Med. 48, 1013-1023 (2010).
34. Kim, S. R. et al. Selective COX-2 inhibitors modulate cellular senescence in human dermal fibroblasts in a catalytic activity-independent manner. Mech. Ageing Dev. 129, 706-713 (2008).
35. Han, S. & Roman, J. COX-2 inhibitors suppress lung cancer cell growth by inducing p21 via COX-2 independent signals. Lung Cancer 51, 283-296 (2006).
36. Roh, G. S. et al. Anti-inflammatory effects of celecoxib in rat lungs with smokeinduced emphysema. Am. J. Physiol. Lung Cell Mol. Physiol. 299, L184-L191 (2010).
37. Liu, G. et al. Kinase AKT1 negatively controls neutrophil recruitment and function in mice. J. Immunol. 191, 2680-2690 (2013).
38. Egan, M. How useful are cystic fibrosis mouse models? Drug Disco. Today Dis. Models 6, 35-41 (2009).
39. van Heeckeren, A. et al. Excessive inflammatory response of cystic fibrosis mice to bronchopulmonary infection with Pseudomonas aeruginosa. J. Clin. Invest. 100, 2810-2815 (1997).
40. Dimagno, M. J. et al. A proinflammatory, antiapoptotic phenotype underlies the susceptibility to acute pancreatitis in cystic fibrosis transmembrane regulator (-/-) mice. Gastroenterology 129, 665-681 (2005).
41. Becker, K. A., Tummler, B., Gulbins, E. & Grassme, H. Accumulation of ceramide in the trachea and intestine of cystic fibrosis mice causes inflammation and cell death. Biochem. Biophys. Res. Commun. 403, 368-374 (2010).
42. Di, A. et al. CFTR regulates phagosome acidification in macrophages and alters bactericidal activity. Nat. Cell Biol. 8, 933-944 (2006).
43. Sorio, C. et al. Defective CFTR expression and function are detectable in blood monocytes: development of a new blood test for cystic fibrosis. PLoS ONE 6, e22212 (2011).
44. van de Weert-van Leeuwen, P. B. et al. Optimal Complement-Mediated Phagocytosis of Pseudomonas aeruginosa by Monocytes is CFTR-Dependent. Am. J. Respir. Cell Mol. Biol. 49, 463-470 (2013).
45. Del Porto, P. et al. Dysfunctional CFTR alters the bactericidal activity of human macrophages against Pseudomonas aeruginosa. PLoS ONE 6, e19970 (2011).
46. Abdulrahman, B. A. et al. Autophagy stimulation by rapamycin suppresses lung inflammation and infection by Burkholderia cenocepacia in a model of cystic fibrosis. Autophagy 7, 1359-1370 (2011).
47. Harris, J., Werling, D., Hope, J. C., Taylor, G. & Howard, C. J. Caveolae and caveolin in immune cells: distribution and functions. Trends Immunol. 23, 158-164 (2002).
48. Gadjeva, M., Paradis-Bleau, C., Priebe, G. P., Fichorova, R. & Pier, G. B. Caveolin-1 modifies the immunity to Pseudomonas aeruginosa. J. Immunol. 184, 296-302 (2010).
49. Yuan, K. et al. Elevated inflammatory response in caveolin-1-deficient mice with Pseudomonas aeruginosa infection is mediated by STAT3 protein and nuclear factor kappaB (NF-kappaB). J. Biol. Chem. 286, 21814-21825 (2011).
50. Peffer, M. E. et al. Caveolin-1 regulates genomic action of the glucocorticoid receptor in neural stem cells. Mol. Cell. Biol 34, 2611-2623 (2014).
51. Le Saux, C. J. et al. Down-regulation of caveolin-1, an inhibitor of transforming growth factor-beta signaling, in acute allergen-induced airway remodeling. J. Biol. Chem. 283, 5760-5768 (2008).
52. Harris, W. T. et al. Myofibroblast differentiation and enhanced TGF-B signaling in cystic fibrosis lung disease. PLoS One 8, e70196 (2013).
53. Yi, H. et al. Differential roles of miR-199a-5p in radiation-induced autophagy in breast cancer cells. FEBS Lett. 587, 436-443 (2013).
54. Eto, K., Goto, S., Nakashima, W., Ura, Y. & Abe, S. I. Loss of programmed cell death 4 induces apoptosis by promoting the translation of procaspase-3 mRNA. Cell Death Differ. 19, 573-581 (2012).
55. Luciani, A. et al. Defective CFTR induces aggresome formation and lung inflammation in cystic fibrosis through ROS-mediated autophagy inhibition. Nat. Cell Biol. 12, 863-875 (2010).
56. Legendre, C., Mooij, M. J., Adams, C. & O'Gara, F. Impaired expression of hypoxia-inducible factor-1alpha in cystic fibrosis airway epithelial cells-a role for HIF-1 in the pathophysiology of CF? J. Cyst. Fibros. 10, 286-290 (2011).
57. Bessich, J. L., Nymon, A. B., Moulton, L. A., Dorman, D. & Ashare, A. Low levels of insulin-like growth factor-1 contribute to alveolar macrophage dysfunction in cystic fibrosis. J. Immunol. 191, 378-385 (2013).
58. Villella, V. R. et al. Disease-relevant proteostasis regulation of cystic fibrosis transmembrane conductance regulator. Cell Death Differ 20, 1101-1115 (2013).
59. Chen, J. et al. CFTR negatively regulates cyclooxygenase-2-PGE(2) positive feedback loop in inflammation. J. Cell Physiol. 227, 2759-2766 (2012).
60. Maier, T. J. et al. Cellular membranes function as a storage compartment for celecoxib. J. Mol. Med. (Berl. ) 87, 981-993 (2009).
61. Sade, A., Banerjee, S. & Severcan, F. Effects of the non-steroidal antiinflammatory drug celecoxib on cholesterol containing distearoyl phosphatidylcholine membranes. Spectroscopy 25, 177-185 (2011).
62. Zemel, B. S., Jawad, A. F., FitzSimmons, S. & Stallings, V. A. Longitudinal relationship among growth, nutritional status, and pulmonary function in children with cystic fibrosis: analysis of the Cystic Fibrosis Foundation National CF Patient Registry. J. Pediatr. 137, 374-380 (2000).
63. Rosenberg, L. A., Schluchter, M. D., Parlow, A. F. & Drumm, M. L. Mouse as a model of growth retardation in cystic fibrosis. Pediatr. Res. 59, 191-195 (2006).
64. Guo, S. Insulin signaling, resistance, and the metabolic syndrome: insights from mouse models into disease mechanisms. J. Endocrinol. 220, T1-T23 (2014).
65. McGettigan, P. & Henry, D. Cardiovascular risk and inhibition of cyclooxygenase: a systematic review of the observational studies of selective and nonselective inhibitors of cyclooxygenase 2. JAMA 296, 1633-1644 (2006).
66. Tourkina, E. et al. Caveolin-1 regulates leucocyte behaviour in fibrotic lung disease. Ann. Rheum. Dis. 69, 1220-1226 (2010).
67. Bains, S. N. et al. Loss of caveolin-1 from bronchial epithelial cells and monocytes in human subjects with asthma. Allergy 67, 1601-1604 (2012).
68. Rab, A. et al. Cigarette smoke and CFTR: implications in the pathogenesis of COPD. Am. J. Physiol. Lung Cell Mol. Physiol. 305, L530-L541 (2013).
69. Cheng, J. et al. An extensive network of TET2-targeting microRNAs regulates malignant hematopoiesis. Cell Rep. 5, 471-481 (2013).
70. Cho, H., Thorvaldsen, J. L., Chu, Q., Feng, F. & Birnbaum, M. J. Akt1/ PKBalpha is required for normal growth but dispensable for maintenance of glucose homeostasis in mice. J. Biol. Chem. 276, 38349-38352 (2001).